



**HAL**  
open science

## Primary inefficacy of TNF inhibitors in patients with axial spondyloarthritis: a long-term follow-up of 25 patients

Sandra Kossi, Sabrina Dadoun, Guillaume Geri, Aurore Hermet, Bruno Fautrel, Maxime Dougados, Laure Gossec

### ► To cite this version:

Sandra Kossi, Sabrina Dadoun, Guillaume Geri, Aurore Hermet, Bruno Fautrel, et al.. Primary inefficacy of TNF inhibitors in patients with axial spondyloarthritis: a long-term follow-up of 25 patients. *Rheumatology*, 2017, 56 (6), pp.896-900. 10.1093/rheumatology/kew456 . hal-01547415

**HAL Id: hal-01547415**

**<https://hal.sorbonne-universite.fr/hal-01547415>**

Submitted on 26 Jun 2017

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## **Primary inefficacy of TNF inhibitors in patients with axial spondyloarthritis: a long term follow up of 25 patients**

Sandra Kossi<sup>1, 2</sup>, Sabrina Dadoun<sup>1, 3</sup>, Guillaume Geri<sup>4</sup>, Aurore Hermet<sup>1</sup>, Bruno Fautrel<sup>1, 3</sup>, Maxime Dougados<sup>5</sup>, Laure Gossec<sup>1, 3</sup>

<sup>1</sup>Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France

<sup>2</sup>Department of Rheumatology, Hôpital Cochin. Assistance Publique - Hopitaux de Paris, Paris, France

<sup>3</sup>Department of Rheumatology, Pitié Salpêtrière Hospital, Assistance Publique – Hopitaux de Paris, Paris, France

<sup>4</sup>Paris Descartes University, Medicine Faculty, Assistance Publique – Hopitaux de Paris, Rheumatology B department, Cochin Hospital, Paris France

<sup>5</sup>Paris Descartes University. Departement of Rheumatology -Hôpital Cochin. Assistance Publique – Hopitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris- Cité. Paris, France

### **Correspondence to :**

Laure Gossec, Université Pierre et Marie Curie - Hôpital Pitié-Salpêtrière Service de Rhumatologie Pavillon Benjamin Delessert 2e étage 47-83, boulevard de l'Hôpital 75013 Paris

[laure.gossec@aphp.fr](mailto:laure.gossec@aphp.fr) Tel : [+33 1 42 17 84 21](tel:+33142178421)

**Running title:** Primary inefficacy of TNF inhibitors in axSpA

## **ABSTRACT**

**Objectives:** Primary inefficacy of TNF inhibitors (TNFi) in axial spondyloarthritis (AxSpA) is infrequent. The objective was to assess the long-term evolution and final diagnosis of patients with primary inefficacy to TNFi in axSpA.

**Methods:** Systematic retrospective study of all patients receiving a TNFi for axSpA in one tertiary referral centre. Patients had axSpA according to the rheumatologist and were started on a first course of TNFi according to usual practice. If treatment was interrupted at 3 months for inefficacy by the rheumatologist, this was defined as primary inefficacy. Five to 10 years later, these patients were re-evaluated.

**Results:** Of 222 patients receiving a first TNFi for axSpA, 27 (12%) were considered as having primary inefficacy. These patients were more often females (48 vs 27%,  $p=0.04$ ), had higher functional impairment (Bath Ankylosing Spondylitis Functional Index (0-100) 68 vs 42,  $p=0.001$ ) and less increased CRP (50% vs 78%,  $p=0.008$ .) At the follow-up, 25 (92%) patients were re-evaluated: the diagnosis of axSpA was confirmed for 21/25 (84%) patients according to the ASAS criteria and 20/25 (80%) patients according to the rheumatologist; but 18/25 (72%) had at least one other cause of symptoms among osteoarthritis, widespread pain syndrome or depression. A second TNFi was prescribed for 16 patients and was efficacious for 9 (56%).

**Conclusion:** Most patients with primary inefficacy had a confirmed diagnosis of axSpA but often had other causes of pain. We suggest patients with primary inefficacy to TNFi should be screened for comorbidities that may interfere with axSpA activity assessment.

**Key words:** Spondyloarthritis, widespread pain syndrome, diagnosis, classification criteria, TNF inhibitors

### **Key messages**

1. Primary inefficacy of TNF inhibitors in axial spondyloarthritis concerned 12% of 222 patients.
2. Eighty percent of 25 patients with primary inefficacy had a confirmed diagnosis of axSpA when followed-up 5 to 10 years later
3. Eighteen of the 25 patients with primary inefficacy had painful comorbidities such as widespread pain syndrome, depression or osteoarthritis.

## **INTRODUCTION**

TNF inhibitors (TNFi) are extremely effective in axial spondyloarthritis (axSpA). Many studies have shown major improvement in SpA activity after TNFi therapy and currently, it is the only drug therapy approved for axSpA patients with insufficient response to non-steroidal anti-inflammatory drug (NSAIDs) [1]. However, some patients are non-responders: primary inefficacy, i.e., an initial lack of treatment response appears infrequent in axSpA with rates around 5-15% [2-5].

The diagnosis of SpA is difficult and is based on a body of clinical arguments associated with laboratory tests and radiological signs [6-8]; several of the clinical criteria contributing to the diagnosis of axSpA, such as enthesitis pain, lack specificity [6]. Furthermore, some frequent diseases or conditions such as osteoarthritis, widespread pain syndrome and depression could interfere either with the activity of SpA (falsely heightened disease activity) or with the response to TNFi (falsely heightened inefficacy) [9-11]. Thus, considering the rarity of primary inefficacy and the difficulty to diagnose axSpA, it seemed useful to explore the cases of primary inefficacy to TNFi in axSpA: who are these patients who have primary inefficacy? What are their demographic and disease characteristics and their final diagnosis? Do they have comorbidities? Is a second course of TNFi of interest in these patients?

The objective of the present study was to describe axSpA patients with primary inefficacy after the first TNFi, 5 to 10 years after their prescription, in terms of diagnosis, comorbidities and current management.

## **PATIENTS AND METHODS**

### *Study design*

Systematic retrospective and prospective study conducted in one tertiary care centre in Paris, France.

### *Population*

All patients with a diagnosis of axSpA according to an expert rheumatologist Amor criteria and receiving a first TNFi in the context of usual practice between 2004 and 2009 in the centre were analysed. The available information was retrospectively collected from the medical files [3]. For the present study, the focus was on those patients who had primary inefficacy to this first TNFi. Primary inefficacy was defined here as treatment interruption 3-4 months after treatment onset, with a

rheumatologist assessment in the medical file of lack of efficacy as reason for drug interruption. The rheumatologist reason to stop the treatment was based on a mixture of efficacy (assessed by BASDAI) as well as patient preference, in the context of usual practice.

#### *Data collected at baseline*

At baseline, demographic and disease (type of disease, presence of extra articular signs, HLAB27 status, the presence of imaging sign and of elevated acute phase reactants in particular C-Reactive protein (CRP) characteristics were collected .

#### *Long-term follow up (prospective phase)*

In 2013-2014, patients with primary inefficacy were contacted by letter and seen in outpatient clinic if possible for clinical examination and medical interview. If this was not possible, they were contacted by telephone and asked to fill in a questionnaire. If the patients did not answer the letter or the 2 reminders, their general practitioner was contacted to either ask the patient to participate to the study, or give us information on the patient status.

Patients gave their consent for the use of the collected data and the study was conducted in accordance with the Declaration of Helsinki so no separate ethical approval was required

#### *Data collected at follow up*

Disease characteristics were collected including the type of disease (axial only, or associated with enthesitic or peripheral arthritis), the presence of extraarticular signs, the HLAB27 status, the presence of imaging signs (sacroiliitis, syndesmophytes on the most recent available imaging), and of elevated acute phase reactants in particular C-Reactive Protein (CRP). AxSpA disease activity was evaluated through an investigator global visual analog scale (VAS), the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and the BASFI (Bath Ankylosing Spondylitis Functional Index) as well as a full clinical evaluation where possible [12, 13]. ASDAS was not used in 2014 because CRP was not always available. Current treatment was collected including NSAIDs intake, TNFi and type and treatment maintenance.

The association with widespread pain syndrome was assessed with the FIRST questionnaire; this validated questionnaire comprises 6 questions and a score  $\geq 5/6$  is

strongly suggestive of widespread pain syndrome [14]. Concomitant spine or lower-limb osteoarthritis and concomitant or past depression were assessed by the physician (SK) during the visit, or by simple questions by phone and/or in the questionnaire. These data were confirmed where possible in the medical file.

The final diagnosis, i.e., confirmation of axSpA diagnosis or not, was evaluated both by applying the Assessment of SpondyloArthritis (ASAS) classification criteria for axSpA [12] and through the rheumatologist's opinion, based on the full evaluation including clinical assessment, imaging and biological results when available.

The fulfillment of the ASAS classification criteria for axSpA was also checked.

### *Statistical analysis*

Descriptive data were summarised using means and standard deviations (SD) comparisons were performed by parametric tests. For patients who had received a second TNFi, the survival rate at one year was assessed using Kaplan Meier survival curves on SAS version 9.2.

## **RESULTS**

### *SpA patients with primary inefficacy*

Of 222 axSpA patients who received a first TNFi between 2004 and 2008, 27 (12%) interrupted the treatment for primary inefficacy (Table 1) [7]. When compared to the 195 patients not classified as primary inefficacy, these patients were more often female (48% vs 27 % in patients without primary inefficacy,  $p=0.04$ ), were older at initiation of the TNFi (45 vs 39 years,  $p=0.04$ ), had higher BASFI (68 vs 42,  $p=0.03$ ) and less frequently an increased CRP (abnormal value according to the laboratory limits: 33% vs 63%,  $p=0.02$ ). Among the 27 patients with primary inefficacy, fifteen patients (56%) carried the HLA B27 and 18 (67%) had radiographic sacroillitis. There was no assessment of comorbidities in patients who did not have primary inefficacy

### *Long term follow up*

Among these 27 patients with primary inefficacy, twenty five (92%) were re-evaluated after 5 to 10 years (mean follow-up,  $6.0\pm 3.1$  years); 9 with a full clinic exam, 5 through a telephone interview, 5 through a self-reported questionnaire, and 6 were re-evaluated only through the medical file. One patient refused to participate in the

study and 1 patient was lost to follow up. Medical files were used to complement the findings for all patients and for 5 patients, the private practice physician also gave information. Among the 25 patients who were followed-up, thirteen (52%) were women, and mean age at the time of their follow-up was  $52.6 \pm 14.6$  years (Table 2). At the long term follow up, all the patients still presented symptoms and back pain although the level of symptoms was moderate: the mean BASDAI was  $42 \pm 21$ . Concerning their current treatment, nine (36%) were treated with TNFi and 9 (36%) were taking NSAIDs. The other patients were prescribed analgesic drugs and/or non-pharmacological measures.

### *Comorbidities*

Five (20%) patients had widespread pain syndrome according to the FIRST questionnaire; all were female. Ten (40%) patients had osteoarthritis of the lower-limb peripheral joints or of the spine; 8 (32%) patients had a self-declared diagnosis of depression of whom 3 (12%) were taking anti-depressant drugs. Overall, eighteen (72%) patients had at least one of these 3 comorbidities.

These patients had the following characteristics: 9 (36%) carried HLA B27, 12 (48%) had radiographic sacroiliitis, 10 (40%) had an increased CRP, 7 (28%) had a family history of spondyloarthritis and 13 (52%) were considered good responders to NSAIDs.

### *TNFi after primary inefficacy*

In all, 16 (64% of 25) patients switched to another TNFi: 9 (36%) received 2 TNFi and 7 (28%) received 3 or more prescriptions of TNFi. Among the patients who had at least a second TNFi, the treatment was considered efficacious for 9 (56% of 16) patients whereas 7 presented with primary inefficacy to the second TNFi. The retention rate of the second TNFi at one year was 50%. At the time of follow up, 9 (36%) patients were still prescribed a TNFi. Note that overall (patients with primary inefficacy and without), 111 (57%) patients stopped the first TNF inhibitor over duration of follow up with a mean follow up of 29 months (SD: 20.1).

### *Final diagnosis*

In all, 21 (84%) patients satisfied the ASAS classification criteria for axSpA [12]. Furthermore, the diagnosis of axSpA was confirmed according to the

rheumatologist's opinion for 20 (80%) patients. Seventeen (68%) patients fulfilled both conditions.

## **DISCUSSION**

This study confirms the infrequent nature of primary inefficacy of TNFi in axSpA (12%) and shows that most of the patients with primary inefficacy to their first TNFi had confirmed axSpA, but also that most of them had comorbidities that could affect axSpA evaluation. This is important because practitioners might consider that primary inefficacy to TNFi leads to reconsidering the diagnosis of SpA (i.e., the notion of a TNFi prescription used as diagnostic test). We suggest here that primary inefficacy should not be considered as equivalent to a diagnostic error, and that a second prescription of TNFi may be of use in such patients, although painful comorbidities should certainly be screened for and taken into account.

This study has strengths and weaknesses. We performed a systematic assessment of all patients receiving a TNFi in a single centre over a defined period of time, allowing a true assessment of the frequency of primary inefficacy. We also managed to reassess almost all the patients with initial primary inefficacy, with a long-term follow-up (mean, 6 years) which allows true reconsideration of the evolution and diagnosis of the patients. Wherever possible, patients were assessed fully through clinical examination, history-taking and imaging at follow up. No such data was available at baseline, in particular there was no assessment of comorbidities. However, the number of patients assessed was low, due to the relative rarity of primary inefficacy. Not all patients accepted to come into the clinic for a full physical assessment; in fact, for 6 patients we could only use the hospital medical file which is a limitation to the systematic character of the study. And finally, the definition used here for primary inefficacy, i.e., an interruption of the TNFi therapy in the 3-4 months following its introduction, with the physician putting as reason primary inefficacy can be discussed. Indeed, 3 months may be a little too short to properly assess the efficacy of TNFi; and a quantitative assessment such as the BASDAI would have been more optimal [15]. However, this is a clinical practice, real-life assessment and we believe that the patients who did interrupt their treatment at 3 months were indeed in a situation of primary inefficacy.



This study showed that patients with axSpA who had primary inefficacy had slightly different clinical characteristics and above all, much comorbidity such as widespread pain syndrome, depression or osteoarthritis. Widespread pain syndrome is not rare in SpA and in particular in the absence of radiological signs of SpA, it raises the question of non-radiographic forms of axSpA [16]. The present study does not give new data regarding non radiographic axSpA but does confirm widespread pain syndrome should be considered when physicians are faced with primary inefficacy in axSpA. The FIRST questionnaire used in the present study is a user-friendly questionnaire for clinical practice, which may be of use for the diagnosis of widespread pain syndrome if its performances are confirmed [14].

If the association of SpA and depressive syndrome is known [17], this study reveals that depression could explain therapeutic failures in axSpA and may support the concept of systematically screening for depression. However, simple-to-use tools to diagnose depression in the setting of a rheumatology clinic, are currently lacking [18]. The present results suggest the importance of a global approach to manage these patients. Widespread pain syndrome, osteoarthritis and depression are very common comorbidities and should systematically be screened and treated, for a better therapeutic management. It would be interesting to do other studies to compare the link between comorbidities and response to TNFi.

The present study indicated a switch to a second TNFi may be worthwhile, for patients who show lack of response to a first TNFi. Indeed, in the present study, sixteen patients received a second TNFi and importantly, the treatment was considered effective in 9 (56%) patients. Although previous studies had indicated the efficacy of TNFi switches in axSpA, this is the first study to specifically look at patients with primary inefficacy to a first TNFi [2-5].

The fact that patients who underwent primary inefficacy to their first TNFi often have a confirmed diagnosis of axSpA confirms the TNF pathway is not the only one involved in these pathologies [19], explaining why some patients do not respond to TNFi therapy. Data regarding the efficacy of new therapeutics developed against the IL17/IL23 pathway in these patients, would be of interest [19].

In conclusion, SpA, like other chronic inflammatory diseases, justifies a holistic approach with appropriate assessment and management of potential comorbidities. Primary inefficacy of a first TNFi should not bar a second TNFi prescription but a

Careful assessment of potentially painful comorbid conditions is useful in such a situation.

**Funding:** This study was funded by the Assistance Publique des Hôpitaux de Paris (AP-HP).

## References

1. Braun J, Davis J, Dougados M, Sieper J, Van der Linden S, Van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. *Ann Rheum Dis.* 2006; 65(3):316-20.
2. Lie E, Van der Heijde D, Uhlig T et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. *Ann Rheum Dis.* 2011; 70(1): 157-63.
3. Dadoun S, Geri G, Paternotte S, Dougados M, Gossec L. Switching between tumour necrosis factor blockers in spondyloarthritis: a retrospective monocentre study of 222 patients. *Clin Exp Rheumatol.* 2011; 29(6):1010-3.
4. Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, et al. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. *Rheumatology (Oxford).* 2008; 47(6):897-900.
5. Paccou J, Solau-Gervais E, Houvenagel E et al. Efficacy in current practice of switching between anti-tumour necrosis factor-  $\alpha$  agents in spondyloarthropathies. *Rheumatology (Oxford).* 2011; 50(4):714-20.
6. Amor B, Dougados M, Mijiyawa M. Criteria of the classification of spondylarthropathies. *Rev Rhum Mal Osteoartic.* 1990; 57(2):85-9.
7. Moll JM..New criteria for the diagnosis of ankylosing spondylitis. *Scand J Rheumatol Suppl.* 1987; 65:12-24.
8. Rudwaleit M, van der Heijde D, Landewé R et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. *Ann Rheum Dis.* 2011;70(1):25-31.
9. Azevedo VF, Paiva Edos S, Felipe LR, Moreira RA. Occurrence of fibromyalgia in patients with ankylosing spondylitis. *Rev Bras Reumatol.* 2010; 50(6): 646-50.

10. Salaffi F, De Angelis R, Carotti M, Gutierrez M, Sarzi-Puttini P, Atzeni F. Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity. *Rheumatol Int.* 2014; 34(8):1103-10.
11. Aloush V, Ablin JN, Reitblat T, Caspi D, Elkayam O. Fibromyalgia in women with ankylosing spondylitis. *Rheumatol Int.* 2007; 27(9): 865-8.
12. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A . A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. *J Rheumatol.* 1994; 21(12):2286-91
13. Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. *J Rheumatol.* 1994; 21(12):2281-5.
14. Perrot S, Bouhassira D, Fermanian J. Development and validation of the Fibromyalgia Rapid Screening Tool (FiRST). *Pain.* 2010; 150(2):250-6
15. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. *Ann Rheum Dis.* 2004; 63(6):665-70
16. Erbil J, Espinoza LR.  
Nonradiographic axial spondyloarthritis background and confounding factors of this new terminology: an appraisal .*Clin Rheumatol.* 2015; 34(3):407-11.
17. Meesters JJ, Bremander A, Bergman S, Petersson IF, Turkiewicz A, Englund M  
The risk for depression in patients with ankylosing spondylitis: a population-based cohort study. *Arthritis Res Ther.* 2014; 16(5):418
18. Baillet A, Gossec L, Carmona L et al. EULAR points to consider for reporting, screening and preventing selected comorbidities in chronic inflammatory rheumatic diseases in clinical practice. *ARD* 2015 (submitted for publication).
19. Smith J, Colbert R. The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. *Arthritis Rheumatol.* 2014; 66(2) 231-41.

**Table 1: Comparison between axSpA patients with and without primary inefficacy to a first TNFi**

Increased CRP: value above the laboratory upper limit of norm

	Patients with primary inefficacy n=27	Patients without primary inefficacy n=195	P value
Age at first TNFi introduction, years, mean (SD)	45 (14)	39 (12)	0.04
Female, n (%)	13 (48)	53 (27)	0.04
BASDAI (0-100) at introduction of first TNFi, mean (SD)	48 (19)	49 (20)	0.9
BASFI (0-100) at introduction of first TNFi, mean (SD)	68 (28)	42 (21)	0.03
Increased CRP, n (%)	9 (33)	123 (63)	0.02
HLAB27 presence, n (%)	15 (56)	141 (72)	0.1
Radiographic sacroillitis, n (%)	18 (67)	157 (81)	0.2
Axial involvement at time of TNFi introduction, n (%)	26 (96)	192 (98)	0.4
History of peripheral arthritis, n (%)	18 (67)	105 (54)	0.3
History of psoriasis, n (%)	4 (15)	35 (18)	1
History of inflammatory bowel disease, n (%)	5 (19)	20 (10)	0.2
History of enthesitic pain, n (%)	16 (59)	87 (45)	0.2
History of uveitis, n (%)	5 (19)	49 (25)	0.6

**Table 2. Long term outcomes of 25 patients with primary inefficacy to the first TNFi**

Characteristic at time of follow-up	All patients with follow up n=25
Peripheral arthritis since first assessment, n (%) <sup>a</sup>	0
Enthesitis since first assessment, n (%)	1 (4)
Uveitis since first assessment, n (%)	2 (8)
Inflammatory bowel disease since first assessment, n	0
Psoriasis since first assessment, n (%)	1(4)
Increased CRP at follow up, n (%)	3 (12)
CRP, mg/l, mean (SD) [n data available]	8 (11) [11]
Pain VAS, mean (SD) [n data available]	44 (26) [18]
Global assessment of disease activity by patient, VAS, mean (SD) [n data available]	57 (33) [15]
BASDAI (0-100), mean (SD) [n data available]	42 (21) [16]
BASFI (0-100), mean (SD) [n data available]	40 (27) [15]
Current TNFi treatment, n (%)	9 (36)

<sup>a</sup>Since first assessment: Occurrence of this manifestation over follow up period (between interruption of the first TNF I and long-term follow up assessment). VAS :visual analog scale.